DRUG · Mapped RxNorm record
Capmatinib
Normalized identity: capmatinibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
NCT04460729
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non-small Cell Lung Carcinoma (NSCLC)unresolved
Interventions
CapmatinibDRUG · verified · RxNorm: capmatinib
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04460729 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.